FOXC2 and neoplasm: Furthermore, the PDGFR-β inhibitor sunitinib reduced tumor growth and metastasis of FOXC2-expressing tumor cells [37], but given our findings it is most likely the effects mediated by sunitinib in these studies are a consequence of complex RTK inhibition and not direct PDGFR-β inhibition.